



## ASX Announcement

23 September 2024

### Date of AGM and Closing Date for Director Nominations

---

In accordance with ASX Listing Rule 3.13.1, **Invex Therapeutics Limited** (ASX: IXC) (**Company**) advises that the Annual General Meeting of the Company will be held on Tuesday, 26 November 2024.

A notice of meeting for the Annual General Meeting (**AGM**) is being prepared by the Company and will be announced to ASX and provided to Shareholders in October 2024.

An item of business at the AGM will be the election of Directors. The closing date for the receipt of nominations for the election of Directors is Tuesday, 8 October 2024.

Any nominations must be received no later than 5:00pm (Perth time) on Tuesday, 8 October 2024 at the Company's registered office.

Shareholders will be advised of further details regarding the AGM in a separate Notice of Meeting

***This release dated 23 September has been authorised for lodgement to the ASX by Narelle Warren, Company Secretary***

**ENDS**

---

#### For more information, please contact:

##### Company/Investors

Dr Thomas Duthy  
Executive Director  
[tduthy@invextherapeutics.com](mailto:tduthy@invextherapeutics.com)  
+61 402 493 727

##### Media

Margie Livingston  
Ignite Communications  
[margie@ignitecommunications.com.au](mailto:margie@ignitecommunications.com.au)  
+61 438 661 131

To subscribe to Invex email alerts, please visit [www.invextherapeutics.com](http://www.invextherapeutics.com) and follow us on Twitter **@InvexThera\_ASX**

### About Invex Therapeutics Ltd

---

Invex is a biopharmaceutical company focused on the repurposing of an already approved drug, Exenatide, for efficacious treatment of neurological conditions derived from or involving raised intracranial pressure, such as acute stroke and traumatic brain injury. Invex has trademarked its repurposed Exenatide as Presendin™. [www.invextherapeutics.com](http://www.invextherapeutics.com)